E2-based mRNA vaccine encapsulated in lipid nanoparticles protects pigs against classical swine fever virus

Ji Liu, Yingju Xia, Chuanwen Tian, Zhiqiang Chen, Weiqiang Guo, Yingnan Liu, Jing Wen, Zhenhua Xie, Jinzhong Lin, Jiaxin Li, Hongjun Chen, Yebing LiuJournal of Virology 2025 · DOI

TL;DR

Researchers have developed a novel mRNA vaccine targeting the E2 glycoprotein of the classical swine fever virus (CSFV). This lipid nanoparticle-encapsulated mRNA vaccine, particularly the E2tm variant, demonstrated robust immunogenicity and provided significant protection against CSFV challenge in pigs, offering a promising alternative to existing vaccination strategies.

What Problem Does This Paper Address?

Classical swine fever (CSF) is a highly contagious and economically devastating disease affecting pigs worldwide. Current vaccines, including live attenuated and subunit vaccines, have limitations. Live attenuated vaccines can be affected by maternal antibodies and lack serological markers to distinguish between infected and vaccinated animals. Subunit vaccines often require higher doses for comparable efficacy. This creates an urgent need for safer, more effective, and potentially differentiating vaccination strategies against CSFV. The study aims to address this by exploring the potential of mRNA vaccine technology.

Methods

The researchers designed and synthesized three mRNA constructs encoding different versions of the CSFV E2 glycoprotein:

  • E2_EX: Encodes the E2 ectodomain.
  • E2tm: Encodes the E2 ectodomain fused with the transmembrane region of the Porcine Epidemic Diarrhea Virus (PEDV) S2 protein.
  • E2tm-HA: Encodes the E2 ectodomain fused with the transmembrane region of the Influenza virus HA protein.

These mRNA sequences were encapsulated into lipid nanoparticles (LNPs) to create the vaccine candidates. The study involved:

  • In vitro characterization: Assessing particle size and polymer dispersity index (PDI) of the LNPs, and confirming protein expression in HEK293T cells via immunofluorescence assay (IFA) and western blotting.
  • Animal immunization: Pigs were immunized with the mRNA vaccines, a commercial E2 subunit vaccine, or the live attenuated C-strain vaccine.
  • Immunogenicity assessment: Serum samples were collected at various time points post-immunization and tested for CSFV-specific antibodies using a blocking ELISA and for neutralizing antibodies (NAb) via serum neutralization assays. The impact of maternal antibodies was also investigated in piglets.
  • Nucleotide modification evaluation: A pseudouridine (Ψ)-modified E2tm mRNA vaccine ("E2tm) was generated and compared to the unmodified E2tm vaccine to assess the effect of nucleotide modification on immunogenicity and antibody persistence. Cellular immune responses were evaluated using an IFN-γ ELISpot assay.
  • Challenge study: Vaccinated pigs were challenged with a virulent CSFV strain, and their survival, rectal temperatures, clinical signs, and viral loads (in blood, oral, nasal, anal swabs, and tissues) were monitored.

Datasets

Not discussed in the paper. The study utilized experimental animal models (pigs and cell lines) and standard laboratory reagents.

Key Insights and Ideas

  • Transmembrane region is key for E2 immunogenicity: Fusing the E2 ectodomain with specific transmembrane regions (PEDV S2 or Influenza HA) significantly improved its expression and immunogenicity compared to the E2 ectodomain alone. The PEDV S2 transmembrane region (E2tm) proved particularly effective.
  • mRNA vaccine overcomes maternal antibodies: The E2tm mRNA vaccine demonstrated robust immunogenicity in piglets, even in the presence of pre-existing maternal antibodies, a common challenge for traditional vaccines.
  • Unmodified mRNA shows superior cellular immunity: Interestingly, the unmodified E2tm mRNA vaccine elicited stronger IFN-γ secreting T cell responses compared to its pseudouridine-modified counterpart, suggesting that the intrinsic immunostimulatory properties of unmodified RNA might be beneficial for cellular immunity.
  • Optimal dose for protection: A higher dose (150 µg) of the E2tm mRNA vaccine provided superior protection, leading to complete viral RNA clearance in tissues and significantly reduced viral shedding.

Key Results

  • E2tm vaccine elicits strongest antibody response: The E2tm mRNA vaccine induced significantly higher CSFV-specific antibody blocking rates and neutralizing antibody titers compared to E2_EX, E2tm-HA, E2 subunit, and C-strain vaccines.
  • Maternal antibodies do not impair E2tm efficacy: In piglets, the E2tm mRNA vaccine maintained high antibody positivity rates and neutralizing antibody titers, unaffected by maternal antibodies.
  • Nucleotide modification impact: While both modified ("E2tm) and unmodified (E2tm) mRNA vaccines provided protection, the 150 µg dose of the unmodified E2tm vaccine resulted in more sustained antibody levels and superior cellular immune responses.
  • Complete protection in challenge study: Pigs vaccinated with the 150 µg E2tm mRNA vaccine survived the CSFV challenge, showed no elevated temperatures or clinical signs, and had undetectable viral RNA in blood, swabs, and all tested tissues at 16 days post-challenge. Lower doses and the modified vaccine also provided significant protection, but not to the same extent as the high-dose unmodified E2tm.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Safety evaluation: Further studies are needed to assess the safety of the vaccine in piglets and pregnant sows.
  • Dose optimization: Determining the minimum effective dose for efficient vaccination efficacy is crucial.
  • Single-dose efficacy: Evaluating the efficacy of a single-dose vaccination strategy would be beneficial.
  • Comparative challenge studies: Direct comparison with other established conventional vaccines is warranted.
  • Mechanism of enhanced immunogenicity: The precise mechanisms underlying the enhanced immunogenicity of the unmodified E2tm mRNA vaccine require further investigation.
  • Practical implementation: Challenges related to the cold chain requirements for mRNA vaccines need to be addressed for widespread veterinary application, although recent advances in lyophilization technology offer promise.

Summary updated

Abstract

Classical swine fever virus (CSFV) remains a significant threat to the global pig industry. While live attenuated and subunit vaccines are currently in use, there is an urgent need for more effective and safer vaccination strategies. Here, we present a novel mRNA vaccine encoding the CSFV E2 glycoprotein, which provides protective immunity against the CSFV challenge in pigs. Our findings underscore the promising efficacy of this mRNA-based vaccine platform and offer an alternative strategy for CSFV prevention and control.
BibTeX
@article{liu2025e,
  author = {Ji Liu and Yingju Xia and Chuanwen Tian and Zhiqiang Chen and Weiqiang Guo and Yingnan Liu and Jing Wen and Zhenhua Xie and Jinzhong Lin and Jiaxin Li and Hongjun Chen and Yebing Liu},
  title = {{E2-based mRNA vaccine encapsulated in lipid nanoparticles protects pigs against classical swine fever virus}},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.00978-25},
}
Figure